+82-2-907-3356
passpuri@l-base.comLifesaving
Beyond Advancement, Science & Excellence
FIRST-IN-CLASS
DRUG DEVELOPMENT FOR TOMORROW’S MIRACLE
L-BASE
Making the difference in Cancer Therapy
OUR TECHNOLOGY
-
For the first
time in the world -
L-Base is a biotech company specialized in innovative R&D of cancer drugs that achieved
the World's first cancer-specific autophagy inhibitor drug.
- CAGE
-
a cancer testis antigen, discovered as a
new target of L-Base in 2002 that generally
expressed in cancer, but
not in normal tissues.
- CAGEpep®
-
a NanoBRET system that can screen the
inhibitory effect of L-Base new candidate drug
on binding of the proteins to the CAGE.
- Autophagy
-
a system that removes waste from cells and
recycles them. L-Base new candidate drug
maintains autophagy in normal cells and
inhibit in cancer cells.
ABOUT
- Company
-
L-Base is developing CAGE-derived peptide-based therapeutics
to overcome resistance to existing anticancer drugs.
